Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ross Kerns (NPI 1023018728)

Field	Value
Entity Type	Individual
Organization	Ross Kerns
Address	9957 Sherrill Blvd
City	Knoxville
State	TN
ZIP	37932
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 26, 2005

Payer Source	Total Paid
Medicare	$4.5M
Medicaid	$0

Key Findings

ROSS KERNS is a hematology & oncology physician with an NPI enumerated on 2005-07-26 (~21 years ago) and has reported $4.5M in total Medicare revenue with no Medicaid billing on file. The absence of any Medicaid claims makes this effectively a single-payer (Medicare) billing profile at the reported scale, concentrating the provider’s public-payer exposure in Medicare alone.

Revenue concentration is high: the precomputed top three Medicare codes account for 58.8% of this provider’s Medicare revenue, driven by J9144 ($1.1M, 26.0%), J9271 ($774K, 18.1%), and J0897 ($631.8K, 14.7%). This concentration indicates that a majority of Medicare dollars come from a small set of high-cost injectable therapies.

The code mix identifies an infusion-heavy oncology practice focused on high-cost monoclonal antibodies and supportive biologics: J9144 (daratumumab), J9271 (pembrolizumab), and J0897 (denosumab) are the top revenue drivers, and the presence of administration and chemotherapy procedure codes (e.g., 96413, 96365, 96417) alongside E/M codes suggests integrated office-based infusion services with onsite clinical management. The practice also bills for supportive therapies such as immune globulin (J1569) and iron formulations (J1437), reinforcing a combined oncology and supportive-care service line.

Competitive standing is mixed by code: J9144 ranks #18 of 615 providers nationally (97th percentile) and is noted as above typical national volume, while J0897 ranks #66 of 10057 providers (99th percentile) and is labeled an "extreme outlier," indicating unusually high denosumab use relative to peers. By contrast, J9271 sits at #502 of 1841 providers (72th percentile) and is described as a typical, unremarkable volume for that code, so the provider is dominant on some biologics but typical on others.

Multiple administration and chemotherapy procedure codes are extreme outliers or notably above typical national volume, consistent with high infusion throughput: 96413 ($87.5K) ranks #104 of 7514 providers (99th percentile; extreme outlier), 96417 ($14.9K) ranks #42 of 3014 (99th percentile; extreme outlier), and 96372 ($16.5K) ranks #105 of 58224 providers (100th percentile; extreme outlier). These patterns point to heavy use of both primary and add-on infusion services, implying substantial chair time and nursing resources devoted to infusion care.

Office-based evaluation and management activity is substantial: 99214 accounts for $143.3K (3.3%) and ranks #2921 of 479517 providers (99th percentile; extreme outlier), while 99215 accounts for $69.4K (1.6%) and ranks #1705 of 145531 providers (99th percentile; extreme outlier). High percentile rankings on these complex E/M codes suggest significant longitudinal management of medically complex patients in-office in addition to infusion work.

Supportive care and biosimilar uptake are notable components of the revenue mix: J1569 (immune globulin) contributes $393.7K (9.2%) and ranks #29 of 542 providers (95th percentile; typical, unremarkable volume), and Q5123 (rituximab-arrx biosimilar) contributes $120.4K (2.8%) while ranking #5 of 40 providers (90th percentile; typical, unremarkable volume). These data indicate above-typical provision of immunoglobulin and a relatively prominent position among a small set of providers billing that rituximab biosimilar.

Payer mix and operational risk: with $4.5M in Medicare revenue and no Medicaid billing on file, the provider’s public-payer mix is heavily concentrated in Medicare which may limit exposure to Medicaid populations but also concentrates reimbursement risk and negotiating leverage around Medicare rates and local oncology network positioning. Analysts should treat contracting, patient accessibility for Medicaid populations, and referral sources as potential operational sensitivities given the lack of Medicaid activity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

77 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	29,340	$40	$1.1M
J9271	Injection, pembrolizumab, 1 mg	18,000	$40	$774K
J0897	Injection, denosumab, 1 mg	35,100	$20	$631.8K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	11,930	$30	$393.7K
J1437	Injection, ferric derisomaltose, 10 mg	12,800	$20	$217.6K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	6,340	$30	$158.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,610	$90	$143.3K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	3,440	$40	$120.4K
J3111	Injection, romosozumab-aqqg, 1 mg	14,910	$10	$119.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,310	$90	$111.2K

Showing 1–10 of 77

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 77 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Ross Kerns — 16 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

77 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	22	50	17,400	$40	$776.1K
J9144	1	20	10,080	$40	$466.3K
J3111	12	20	15,540	$10	$256.9K
J1569	3	30	3,030	$40	$175.2K
J1449	1	10	3,630	$30	$98.6K
J1437	3	20	3,700	$20	$86.3K
J0897	1	240	2,940	$20	$85K
Q5123	1	10	1,960	$40	$70.9K
J0881	7	70	19,050	$1	$54.4K
88185	9	30	690	$20	$51.2K

Showing 1–10 of 77

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ross Kerns, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mitchell Martin	TN	Hematology & Oncology Physician	$4.7M	$0
Daniel Ibach	TN	Hematology & Oncology Physician	$4.3M	$0
Yi Feng	TN	Hematology & Oncology Physician	$4M	$0
Tennessee Cancer Specialists PLLC	TN	Hematology & Oncology Physician	$0	$2.7M
Dharmen Patel	TN	Hematology & Oncology Physician	$901.9K	$0
Tracy Dobbs	TN	Medical Oncology Physician	$853.5K	$0
Richard Lee	TN	Hematology & Oncology Physician	$643K	$0
Robert Schumaker	TN	Hematology & Oncology Physician	$587.3K	$0
Anil Tumkur	TN	Hematology & Oncology Physician	$491.1K	$24.3K
Saji Eapen	TN	Hematology & Oncology Physician	$487.3K	$0

Nearby Providers

Other providers in the same ZIP code as Ross Kerns, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Covenant Medical Group, Inc.	TN	Family Medicine Physician	$0	$17.9M
Maxim Healthcare Services, Inc	TN	Home Health Agency	$0	$16.4M
Cde Onsite Senior Services Corporation	TN	In Home Supportive Care Agency	$0	$7.9M
Integrity Laboratories, LLC	TN	Clinical Medical Laboratory	$109.6K	$4.1M
Parkwest Surgery Center LLC	TN	Ambulatory Surgical Clinic/Center	$1.9M	$0
Jeffrey Dell	TN	Gynecology Physician	$438.3K	$0
Contract Health Services, Inc.	TN	Sonography Specialist/Technologist Cardiovascular	$64.1K	$260.1K
Joseph Meyer	TN	Radiation Oncology Physician	$285.1K	$0
Jake Mcmillin	TN	Ophthalmology Physician	$212.1K	$0
Elmer Pinzon	TN	Physical Medicine & Rehabilitation Physician	$65.1K	$0

Ross Kerns — Billing Profile & Reimbursement Data

Sign up for Ross Kerns — Billing Profile & Reimbursement Data policy alerts

Ross Kerns — Billing Profile & Reimbursement Data

Sign up for Ross Kerns — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References